News & Events zu Bluejay Diagnostics Inc (BJDX)BJDXBluejay Diagnostics Inc

Bluejay Diagnostics Inc Trading Halted, News Pending

Bluejay Diagnostics Inc trading halted, news pending

Bluejay Diagnostics Reports Baseline Data from SYMON-II Clinical Study

Bluejay Diagnostics announced baseline clinical characteristics from the SYMON-II clinical validation study, highlighting a substantial and diverse population of critically ill patients and clinically meaningful mortality events for evaluating interleukin-6, or IL-6, as a biomarker associated with 28-day mortality risk in patients with sepsis and septic shock. The current preliminary SYMON-II analysis includes 777 evaluable patients, consisting of 637 28-day survivors and 140 28-day non-survivors, representing an overall 28-day mortality rate of approximately 18%. The study population included patients across a broad spectrum of illness severity, ethnicity and geographical distribution with 39.5% meeting Sepsis-3 criteria for septic shock. The clinical characteristics demonstrate substantial disease burden and severity. 84% of patients had bacterial infection reported, 32.4% had a positive blood culture, and infection was considered highly likely or likely in 86.5% of the study population. Patients who did not survive through 28 days demonstrated greater baseline illness severity. Septic shock was present in 56.4% of non-survivors compared with 35.8% of survivors.

Bluejay Partners with Lovell Government Services for Federal Market Access

Bluejay Diagnostics and Lovell Government Services, a Service-Disabled Veteran-Owned Company specializing in federal healthcare distribution, announced a distribution, co-marketing and strategic partnership designed to support the introduction of Bluejay's products into the U.S. federal healthcare market following applicable FDA clearance or other required regulatory authorization. The partnership is designed to establish a scalable federal market access and procurement infrastructure in advance of potential commercialization. Under the agreement, Lovell will serve as Bluejay's exclusive distributor for federal procurement opportunities requiring or favoring SDVOSB set-aside and preferred status, including opportunities within the U.S. Department of Veterans Affairs, Department of Defense, Military Health Systems and Indian Health Service. Lovell will also have non-exclusive rights to participate in open-market federal, state and local government procurement opportunities. Through the partnership, Lovell will leverage its SDVOSB status, federal contracting capabilities and industry relationships to support market development, facilitate appropriate introductions and pursue federal procurement opportunities for Bluejay.